Progress of SARS-CoV-2 Main protease peptide-like inhibitors
© 2023 John Wiley & Sons Ltd..
The pneumonia outbreak caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection poses a serious threat to people worldwide. Although vaccines have been developed, antiviral drugs are still needed to combat SARS-CoV-2 infection due to the high mutability of the virus. SARS-CoV-2 main protein (Mpro ) is a special cysteine protease that is a key enzyme for SARS-CoV-2 replication. It is encoded by peptides and is responsible for processing peptides into functional proteins, making it an important drug target. The paper reviews the structure and peptide-like inhibitors of SARS-CoV-2 Mpro , also the binding mode and structure-activity relationship between the inhibitors and Mpro are introduced in detail. It is hoped that this review can provide ideas and help for the development of anti-coronavirus drugs such as COVID-19, and help to develop broad-spectrum antiviral drug for the treatment of coronavirus diseases as soon as possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Chemical biology & drug design - 103(2024), 1 vom: 21. Jan., Seite e14425 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Xiaoyong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cbdd.14425 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365732400 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365732400 | ||
| 003 | DE-627 | ||
| 005 | 20240325234504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cbdd.14425 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM365732400 | ||
| 035 | |a (NLM)38082476 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Xiaoyong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress of SARS-CoV-2 Main protease peptide-like inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a The pneumonia outbreak caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection poses a serious threat to people worldwide. Although vaccines have been developed, antiviral drugs are still needed to combat SARS-CoV-2 infection due to the high mutability of the virus. SARS-CoV-2 main protein (Mpro ) is a special cysteine protease that is a key enzyme for SARS-CoV-2 replication. It is encoded by peptides and is responsible for processing peptides into functional proteins, making it an important drug target. The paper reviews the structure and peptide-like inhibitors of SARS-CoV-2 Mpro , also the binding mode and structure-activity relationship between the inhibitors and Mpro are introduced in detail. It is hoped that this review can provide ideas and help for the development of anti-coronavirus drugs such as COVID-19, and help to develop broad-spectrum antiviral drug for the treatment of coronavirus diseases as soon as possible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Mpro | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a peptide-like inhibitor | |
| 650 | 4 | |a structure | |
| 650 | 7 | |a 3C-like proteinase, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a EC 3.4.22.- |2 NLM | |
| 650 | 7 | |a Viral Nonstructural Proteins |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Coronavirus 3C Proteases |2 NLM | |
| 650 | 7 | |a EC 3.4.22.28 |2 NLM | |
| 700 | 1 | |a Ren, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Chaoya |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Zhiyong |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Ziqiao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Bing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical biology & drug design |d 2006 |g 103(2024), 1 vom: 21. Jan., Seite e14425 |w (DE-627)NLM160848377 |x 1747-0285 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:1 |g day:21 |g month:01 |g pages:e14425 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cbdd.14425 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 1 |b 21 |c 01 |h e14425 | ||